CSWYF (China Shineway Pharmaceutical Group) Piotroski F-Score: 7 (As of Jun. 24, 2026) — Near Median


CSWYF China Shineway Pharmaceutical Group Ltd CSWYF
92 GF Score
Price $1.00
GF Value $0.88
! 2 Warning Signs
View Full Analysis

What is China Shineway Pharmaceutical Group Piotroski F-Score?

China Shineway Pharmaceutical Group CSWYF 92 Piotroski F-Score is 7 as of Jun. 24, 2026, which is at its 10-year median of 7.00. GuruFocus rates CSWYF with a GF Score™ of 92/100 and a GF Value™ of $0.88. The stock has 2 warning signs investors should review. Among 981 Drug Manufacturers companies, China Shineway Pharmaceutical Group ranks better than 91.95% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

China Shineway Pharmaceutical Group has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for China Shineway Pharmaceutical Group's Piotroski F-Score or its related term are showing as below:

CSWYF' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of China Shineway Pharmaceutical Group was 8. The lowest was 5. And the median was 7.

China Shineway Pharmaceutical Group  (OTCPK:CSWYF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


China Shineway Pharmaceutical Group Piotroski F-Score Related Terms


China Shineway Pharmaceutical Group Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for China Shineway Pharmaceutical Group's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Shineway Pharmaceutical Group Piotroski F-Score Chart

China Shineway Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 6.00 7.00 5.00 7.00

China Shineway Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 0.00 5.00 0.00 7.00

CSWYF vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Shineway Pharmaceutical Group Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where China Shineway Pharmaceutical Group's Piotroski F-Score falls into.


CSWYF
92GF Score
China Shineway Pharmaceutical Group Ltd CSWYF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was $134.9 Mil.
Cash Flow from Operations was $166.4 Mil.
Revenue was $445.2 Mil.
Gross Profit was $321.8 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (1379.198 + 1530.148) / 2 = $1454.673 Mil.
Total Assets at the begining of this year (Dec24) was $1,379.2 Mil.
Long-Term Debt & Capital Lease Obligation was $0.1 Mil.
Total Current Assets was $1,321.0 Mil.
Total Current Liabilities was $356.4 Mil.
Net Income was $115.4 Mil.

Revenue was $518.9 Mil.
Gross Profit was $388.9 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (1340.858 + 1379.198) / 2 = $1360.028 Mil.
Total Assets at the begining of last year (Dec23) was $1,340.9 Mil.
Long-Term Debt & Capital Lease Obligation was $1.1 Mil.
Total Current Assets was $1,181.0 Mil.
Total Current Liabilities was $336.5 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

China Shineway Pharmaceutical Group's current Net Income (TTM) was 134.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

China Shineway Pharmaceutical Group's current Cash Flow from Operations (TTM) was 166.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=134.874/1379.198
=0.09779162

ROA (Last Year)=Net Income/Total Assets (Dec23)
=115.381/1340.858
=0.08605013

China Shineway Pharmaceutical Group's return on assets of this year was 0.09779162. China Shineway Pharmaceutical Group's return on assets of last year was 0.08605013. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

China Shineway Pharmaceutical Group's current Net Income (TTM) was 134.9. China Shineway Pharmaceutical Group's current Cash Flow from Operations (TTM) was 166.4. ==> 166.4 > 134.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=0.112/1454.673
=7.699E-5

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=1.134/1360.028
=0.00083381

China Shineway Pharmaceutical Group's gearing of this year was 7.699E-5. China Shineway Pharmaceutical Group's gearing of last year was 0.00083381. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=1321.024/356.411
=3.70646248

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=1181.002/336.506
=3.50960161

China Shineway Pharmaceutical Group's current ratio of this year was 3.70646248. China Shineway Pharmaceutical Group's current ratio of last year was 3.50960161. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

China Shineway Pharmaceutical Group's number of shares in issue this year was 755.4. China Shineway Pharmaceutical Group's number of shares in issue last year was 755.4. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=321.758/445.17
=0.72277557

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=388.939/518.912
=0.74952786

China Shineway Pharmaceutical Group's gross margin of this year was 0.72277557. China Shineway Pharmaceutical Group's gross margin of last year was 0.74952786. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=445.17/1379.198
=0.32277454

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=518.912/1340.858
=0.38699997

China Shineway Pharmaceutical Group's asset turnover of this year was 0.32277454. China Shineway Pharmaceutical Group's asset turnover of last year was 0.38699997. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+0+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

China Shineway Pharmaceutical Group has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
China Shineway Pharmaceutical Group (CSWYF) has a Piotroski F-Score of 7 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on China Shineway Pharmaceutical Group and its competitors. This is near median its historical median of 7.00. Over the past decade, China Shineway Pharmaceutical Group's Piotroski F-Score has ranged from 5.00 to 8.00. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #79 out of 981 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is China Shineway Pharmaceutical Group's Piotroski F-Score too high?
China Shineway Pharmaceutical Group's current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. China Shineway Pharmaceutical Group's value of 7 is 40% above this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #79 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #79 out of 981 companies for Piotroski F-Score. This places China Shineway Pharmaceutical Group in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. China Shineway Pharmaceutical Group's value of 7 is 40% above this benchmark. Historically, China Shineway Pharmaceutical Group's own Piotroski F-Score has ranged from 5.00 to 8.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, China Shineway Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYF) has a current Piotroski F-Score of 7. The stock's GF Value™ is $0.88, compared to a current price of $1.00 — trading 14.1% above its estimated fair value. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 40% above the Drug Manufacturers industry median of 5.00. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYF), the current Piotroski F-Score is 7 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Shineway Pharmaceutical Group (CSWYF) Overvalued in 2026?

Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued. The current stock price of $1.00 is trading 14.1% above its estimated GF Value™ of $0.88.

Key valuation signals for CSWYF:

  • Piotroski F-Score: 7 (near median its 10-year median of 7.00)
  • GF Value™: $0.88 vs. price of $1.00 (14.1% above fair value)
  • GF Score™: 92/100 with 2 warning signs
  • Industry Position: 40% above the Drug Manufacturers median (#79 of 981)

No single metric tells the full story. See the CSWYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Shineway Pharmaceutical Group Business Description

Other Exchanges 02877:Hong KongC1S:Germany
Address Luan Cheng, Hebei Province, Shijiazhuang, CHN
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score

Get the complete analysis for CSWYF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price
$0.88
GF Value